SpeeDx announce a collaborative agreement with GSK to supply tests and technology

SpeeDx tests and technology will be used to support GSK antibiotic clinical trials

News provided by

Jun. 25, 2019 10:14

A

Size

A A A A

SYDNEY--(Business Wire / Korea Newswire)--SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has signed a collaborative agreement with GSK, to provide a combination of existing tests and custom test development to support certain GSK antibiotic clinical trials and new product development.

“We welcome this extension of the utility and application of our tests and technology,” said Colin Denver, SpeeDx CEO. “SpeeDx has a demonstrated commitment to improve patient care, and our tests currently used in clinical practice are supporting Resistance Guided Therapy, positively impacting cure rates and helping to minimise the spread of antimicrobial resistant infections.”

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information about SpeeDx please see: https://plexpcr.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20190624005302/en/

Website: https://plexpcr.com/

View Korean version of this release

Contact

SpeeDx
Australia, New Zealand and Europe
Madeline O’Donoghue
+61 406 582 808

RCI Healthcare Public Relations
United States
Rick Roose
+1 415 202 4445

This news is a press release provided by SpeeDx Pty. Ltd.. Korea Newswire follows these editorial guidelines.

SpeeDx Pty. Ltd. News Releases

SpeeDx Build Further Coverage in SARS-CoV-2 Genotyping Reagent Portfolio

SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have further expanded their product line of research reagents for COVID-19 variant analysis to include a key characteristic mutation connected to the SARS-CoV-2 Lambda variant of interest (VOI). The PlexPrime® S...

2021년 10월 7일 14:10

스피덱스, 제2형 중증급성호흡기증후군 코로나19 유전형 시약 포트폴리오의 적용 범위 확대

혁신적인 분자 진단 솔루션 개발 업체 스피덱스(SpeeDx Pty. Ltd)가 코로나19 변이 분석용 연구 시약 제품군을 추가로 확대해 SARS-CoV-2(제2형 중증급성호흡기증후군)의 관심 변이(variant of interest, VOI)인 SARS-CoV-2 람다 변이와 관련한 주요 특성의 변이를 포함하게 됐다. 스피덱스의 PlexPrime® SARS...

2021년 10월 7일 14:10

... More

More News

All News Releases